Gracell Biotechnologies Inc. (GRCL) — Cash Flow-to-Debt Ratio
Gracell Biotechnologies Inc. (GRCL) has a Cash Flow-to-Debt Ratio of -0.33x as of March 2021, meaning its operating cash flow of $-63.95 Million could theoretically repay 0% of its total liabilities ($193.62 Million) in one year. See Gracell Biotechnologies Inc. net asset quality index to measure how much of total assets are equity-financed.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Gracell Biotechnologies Inc. Cash Flow-to-Debt Ratio (2018–2022)
Historical debt coverage capacity for Gracell Biotechnologies Inc. across 5 annual periods. See Gracell Biotechnologies Inc. leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Annual Cash Flow-to-Debt Ratio for Gracell Biotechnologies Inc. (2018–2022)
Year-by-year debt coverage analysis for Gracell Biotechnologies Inc.. For the full cash flow conversion analysis, see GRCL cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2022 | -11.79x | $-3.31 Billion | $280.51 Million | ▼ -801.1% |
| 2021 | -1.31x | $-304.55 Million | $232.77 Million | ▲ +4.1% |
| 2020 | -1.36x | $-198.15 Million | $145.29 Million | ▼ -58.0% |
| 2019 | -0.86x | $-135.39 Million | $156.86 Million | ▼ -103.9% |
| 2018 | -0.42x | $-61.86 Million | $146.13 Million | — |